Journal Information
Vol. 17. Issue 1.
Pages 57-58 (January 2021)
Download PDF
More article options
Vol. 17. Issue 1.
Pages 57-58 (January 2021)
Letter to the Editor
Full text access
Extension of the RENACER Study: 12-Month Efficacy, Safety and Certolizumab PEGol Survival in 501 Rheumatoid Arthritis Patients
Ampliación del estudio RENACER: eficacia, seguridad y supervivencia a 12 meses de 501 pacientes de artritis reumatoide tratados con Certolizumab PEGol
Vicenç Torrente-Segarraa,
Corresponding author
, Manuel Fernández Pradab, Rosa Expósitoc, Noemí Patricia Garrido Puñald, Amalia Sánchez-Andradee, José Ramón Lamúa-Riazuelof, Alejandro Olivég, Juan Víctor Tovarh, on behalf of RENACER Study Group
a Hospital Comarcal Alt Penedès, Spain
b Hospital Universitario de Guadalajara, Spain
c Hospital Comarcal de Laredo, Spain
d Hospital Universitario Virgen del Rocío, Spain
e Complejo Hospital Universitario Lucus Augusti, Spain
f Hospital Universitario del Henares, Spain
g Hospital Germans Tries i Pujol, Spain
h Hospital General Universitario de Elche, Spain
This item has received
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table 1. Baseline and follow-up activity, serological and treatment data.
Full Text
Dear Editor:

Regarding with our previous RENACER (REgistro NAcional CERtolizumab) Study,1 we would like to present data in a larger population of Rheumatoid Arthritis (RA) patients on the use of Certolizumab-PEGol (CZP). CZP is a biological agent approved for RA which inhibits Tumor Necrosis Factor-alpha (TNFi). Its unique molecular structure allows its use in particular situations.2,3 Our study collected data in clinical practice from 2011 to present in 37 different sites in Spain, collecting socio-demographics, smoking status, clinical and safety data at baseline, 3-, 6- and 12-month visits. Clinical outcomes were defined by completion of EULAR Good/Moderate and DAS28 Remission. Drug survival was also assessed (Kaplan–Meier curve). A total of 501 RA patients were included: 78.6% women, mean age 53.6 yr (±13.2 SD), 23% were aged >65 yr; mean disease duration 7.5 yr (±7.3 SD), 27.7% having early RA (<2 yr); prior csDMARD number 1.5 (±1.1 SD); mean prior bDMARD number was 0.8 (±1.2 SD); mean exposure time to CZP was 9.8 months (±3.4 SD); concomitant steroids intake 12.6%, csDMARD 24.2% and csDMARD plus steroids 54.9%; 69.8% never smoked, 12.9% former smoker and 17.3% current smoker. A total of 135 discontinued CZP (27%). Clinical and treatment outcomes are shown in Table 1, statistically significant improvement in all parameters at 12-month visit compared to baseline was observed. 12-month EULAR Response was reached in 69.8% of patients, 64.4% when using CZP as 2nd-line treatment after 1st-bDMARD clinical failure (N=90, data not shown). 12-month DAS28 Remission was achieved in 40.5% of patients (34.4% in 2nd-line). Overall CZP 12-month survival was 73.1%. We found CZP survival rate in bio-naïve patients was higher than in those who used previous bDMARD, 77.2% vs. 68.5% (p=0.029), respectively (Fig. 1). Moreover, the use of CZP in combination to csDMARD showed better DAS28 Remission criteria rate than in monotherapy (p=0.030). Adverse events were reported in 13% of cases, mostly mild or non-life threatening (N=65; 2.4% cutaneous rash, 1% upper respiratory infection, as the most frequents). During the study we observed the following discontinuation reasons: 68 patients (50%) showed secondary inefficacy, 36 (26%) intolerance, 15 (11%) primary inefficacy and 16 (12%) others.

Table 1.

Baseline and follow-up activity, serological and treatment data.

  Baseline  3-month  6-month  12-month  p value 
TJC  9.3±6.2  5.0±5.5  3.9±4.7  3.6±4.9  <0.001 
SJC  6.7±5.1  3.4±4.2  2.4±3.5  2.1±3.3  <0.001 
RF (positive/negative)  53.8%/46.2%  53.2%/46.8%  52.3%/47.7%  49.8%/50.2%  0.165 
CCP antibodies (positive/negative)  68.8%/31.2%  63.6%/36.4%  67.2%/32.8%  62.6%/37.4%  0.300 
ESR  29.2±23.1  23.4±20.6  22.8±21.3  21.3±20.0  <0.001 
CRP (mg/L)  6.9±15.8  4.9±11.1  4.3±10.7  4.3±10.5  <0.001 
Mean Steroids Dose (mg)  7.9±6.2  6.0±5.5  5.1±5.2  4.4±4.8  <0.001 
DAS28  4.7±1.1  3.7±1.3  3.4±1.3  3.2±1.3  <0.001 
DAS28 Remission (%)  –  22.9  31.3  40.5  – 
EULAR Good/Moderate Response (%)  –  54.8  64.8  69.7  – 

Abbreviations: tender joint count (TJC); swollen joint count (SJC); rheumatoid factor (RF); anti-cyclic citrullinated peptide antibodies (CCP); erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); Disease Activity Score 28-joints (DAS28); European League Against Rheumatology (EULAR); milligrams (mg); percentage (%).

Fig. 1.

Comparative cumulative survival between bio-naïve patients and patients that received previous biological therapy.


Since our first publication, two other studies assessing patients treated with CZP have been developed in Italy and Sweden. The Italian study in 278 RA patients found similar EULAR Response rates at one year from CZP onset (66%). The authors also found that clinical response at 3-month visit predicted low disease activity at 12-month assessment (68% as 1st-line treatment).4 The Swedish registry collected data from 945 RA patients that received CZP (57% as 1st-line treatment, 23% as 2nd-line). The authors found a 71% EULAR Response achievement at 6-month visit and better 30-month survival drug on those TNFi-naïve.5 In another clinical trial, a total of 38.1% ACR-50 completion at 12-month assessment was shown, with positive predictive value for those patients who showed a >1.2 points reduction in DAS28 from baseline.6 We conclude that CZP use in severe RA patients should be specially recommended in bio-naïve patients and in those who failed to one TNFi over those who failed to two or more TNFi, with reasonable safety profile. Further studies are recommended in order to establish CZP long-term survival.

V. Torrente-Segarra, A. Urruticoechea Arana, A. Sánchez-Andrade Fernández, J.V. Tovar Beltrán, A. Muñoz Jiménez, A. Martínez-Cristóbal, RENACER Study Group, et al.
RENACER study: assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database.
Mod Rheumatol, 7 (2015), pp. 1-6
J. Flint, S. Panchal, A. Hurrell, M. van de Venne, M. Gayed, K. Schreiber, BSR and BHPR Standards, Guidelines and Audit Working Group, et al.
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: Standard and biologic disease modifying anti-rheumatic drugs and corticosteroids.
Rheumatology (Oxford), 55 (2016), pp. 1693-1697
C. Götestam Skorpen, M. Hoeltzenbein, A. Tincani, R. Fischer-Betz, E. Elefant, C. Chambers, et al.
The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
Ann Rheum Dis, 75 (2016), pp. 795-810
F. Iannone, G. Carlino, A. Marchesoni, P. Sarzi-Puttini, R. Gorla, G. Lapadula, GISEA (Gruppo Italiano di Studio sulle Early Arthritides).
Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA.
Joint Bone Spine, 83 (2016), pp. 721-725
K. Chatzidionysiou, L.E. Kristensen, J. Eriksson, J. Askling, R. van Vollenhoven, ARTIS Group.
Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.
Scand J Rheumatol, 44 (2015), pp. 431-437
F. Berenbaum, T. Pham, P. Claudepierre, T. de Chalus, J.M. Joubert, C. Saadoun, et al.
Early non-response to Certolizumab PEGol in rheumatoid arthritis predicts treatment failure at one year Data from a randomised phase III clinical trial.
Joint Bone Spine, 85 (2018), pp. 59-64
Copyright © 2019. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Reumatología Clínica (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?